Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ValiRxLSE:VAL Earnings Yield (Joel Greenblatt) % is -196.08% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 1,319 Biotechnology companies, ValiRx ranks worse than 96.06% on this metric.
ValiRx's Enterprise Value for the quarter that ended in Dec. 2025 was £1.24 Mil.
ValiRx's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was £-2.41 Mil. ValiRx's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was -196.08%.
The historical rank and industry rank for ValiRx's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
LSE:VAL'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -16350.68 Med: 1547.53 Max: 22103.7
Current: -327.94
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of ValiRx was 22103.70%. The lowest was -16350.68%. And the median was 1547.53%.
LSE:VAL's Earnings Yield (Joel Greenblatt) % is ranked worse than 96.06% of 1319
companies
in the Biotechnology industry
Industry Median: -10.06
vs LSE:VAL: -327.94
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. ValiRx's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
ValiRx Earnings Yield (Joel Greenblatt) % Related Terms
ValiRx Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for ValiRx's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ValiRx's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ValiRx Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ValiRx's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where ValiRx's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
ValiRxs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of -196.08% mean?
ValiRx (LSE:VAL) has a Earnings Yield (Joel Greenblatt) % of -196.08% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on ValiRx and its competitors. According to the industry distribution chart, ValiRx ranks #1267 out of 1319 companies in the Biotechnology industry, placing it in the top 96.1%.
Is ValiRx's Earnings Yield (Joel Greenblatt) % too high?
ValiRx's current Earnings Yield (Joel Greenblatt) % is -196.08%. Based on the distribution chart, ValiRx ranks #1267 out of 1319 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does ValiRx's Earnings Yield (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ValiRx ranks #1267 out of 1319 companies for Earnings Yield (Joel Greenblatt) %. This places ValiRx in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on ValiRx and its competitors. ValiRx's current Earnings Yield (Joel Greenblatt) % is -196.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ValiRx stock overvalued right now?
ValiRx (LSE:VAL) has a current Earnings Yield (Joel Greenblatt) % of -196.08%. The current Earnings Yield (Joel Greenblatt) % is -196.08%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For ValiRx (LSE:VAL), the current Earnings Yield (Joel Greenblatt) % is -196.08% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in their different stages of development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:VAL has been successfully added to your 
